share_log

The Analyst Verdict: Health Catalyst In The Eyes Of 5 Experts

The Analyst Verdict: Health Catalyst In The Eyes Of 5 Experts

分析師意見:health catalyst在5位專家眼中的表現
Benzinga ·  08/09 14:02
Across the recent three months, 5 analysts have shared their insights on Health Catalyst (NASDAQ:HCAT), expressing a variety of opinions spanning from bullish to bearish.
在最近三個月中,5位分析師分享了他們對Health Catalyst(納斯達克股票代碼:HCAT)的見解,表達了從看漲到看跌的各種觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的評級,展示了過去30天情緒的演變,並將其與前幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $11.2, along with a high estimate of $16.00 and a low estimate of $7.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.08%.
分析師提供了更深入的見解,確定了12個月的目標股價,平均目標價爲11.2美元,最高估計爲16.00美元,低估值爲7.00美元。隨着分析師將平均目標股價下調了5.08%,情緒的負面轉變顯而易見。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級:詳細審查
The...
對...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論